Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sera Prognostics, Biomarker Strategies

Premium

Sera Prognostics has named Ilia Ichetovkin vice president of lab operations where he will head development and deployment of the company's CLIA lab services and the commercial launch of its proteomic test to predict preterm birth risk.

Ichetovkin formerly was head of oncology at Vela Diagnostics, director of US lab operations with LabCorp Clinical Trials, and head of clinical diagnostics and biomarker development at Abraxis Bioscience.


Biomarker Strategies has appointed Jack Davis as executive chairman. He will serve as both chairman of the board and as the senior strategic management adviser for the firm.

Davis was a co-founder, president, CEO, chairman, and chief operating officer of Dianon Systems, and he also was division vice president and general manager of Abbott Diagnostics' diagnostic products unit.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.